OncoDaily Pulse

Aug 22, 2025, 10:14

Ari Hakimi: Meet the Experts of VIRO 2025

The Global Voices in Renal Oncology (VIRO) Virtual Congress, organized by OncoDaily, will be held on September 11–12, 2025. Chaired by Dr. Rana R. McKay with co-chair Dr. Yüksel Ürün, this year’s program will feature around 50 leading experts in renal oncology from across the globe, sharing cutting-edge updates and future perspectives.

The congress is free to attend.
Register here: https://forms.gle/qcQyaGMQfHDhanfD9

Co-Chair of VIRO

Images

Name

Rana McKay

Professor of Medicine and Urology at UC San Diego Health Co-leader of the GU Oncology Program at Moores Cancer Center

As Co-Chair of VIRO, Dr. Rana McKay (University of California, San Diego) opened the congress with her talk on
“Future Directions: Emerging Agents and Combinations.”

She emphasized the momentum in renal cell carcinoma (RCC) research, highlighting how novel immunotherapies, targeted drugs, and rational combination strategies are reshaping patient care. Dr. McKay underscored the importance of personalized, biomarker-driven approaches and global collaboration, aiming to optimize survival and quality of life worldwide.

Spotlight on Ari Hakimi

Dr. Ari Hakimi is an Associate Professor and Urologic Surgeon at Memorial Sloan Kettering Cancer Center in New York, internationally recognized for his expertise in the surgical and multidisciplinary management of kidney cancers. His research has significantly advanced understanding of tumor biology, perioperative care, and prognostic modeling in renal cell carcinoma (RCC).

At the Global Voices in Renal Oncology (VIRO) Virtual Congress 2025, Dr. Hakimi will present in Session 2: Risk Stratification and Perioperative Management for Localized Disease on the topic of “Modern Prognostic Models for Localized RCC.” His session will emphasize the evolving role of risk stratification tools in guiding treatment decisions and tailoring perioperative management.

Dr. Hakimi will share insights on

Advances in prognostic models and their application in predicting outcomes for localized RCC.
Integration of clinical, pathological, and molecular factors into modern risk assessment.
Optimizing perioperative strategies through precise patient selection and individualized care.

By highlighting the value of refined prognostic models, Dr. Hakimi underscores the importance of precision in managing localized RCC, ensuring that patients receive the most appropriate care strategies while minimizing overtreatment. His work continues to shape the future of RCC care, bridging surgical expertise with data-driven oncology.